{"id":"NCT03965923","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","briefTitle":"Randomized, Open Label Safety Trial of Dapivirine Vaginal Ring and Oral TRUVADA® Use in Pregnancy","officialTitle":"Phase 3b, Randomized, Open Label Safety Trial of Dapivirine Vaginal Ring and Oral TRUVADA® Use in Pregnancy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-01-09","primaryCompletion":"2024-05-13","completion":"2024-05-13","firstPosted":"2019-05-29","resultsPosted":"2025-08-12","lastUpdate":"2025-08-12"},"enrollment":1104,"design":{"allocation":"RANDOMIZED","model":"SEQUENTIAL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["HIV Infections"],"interventions":[{"type":"DRUG","name":"Dapivirine (DPV) Vaginal Ring (VR)","otherNames":[]},{"type":"DRUG","name":"Truvada Tablet","otherNames":["Emtricitabine/Tenofovir Disoproxil Fumarate","FTC/TDF"]}],"arms":[{"label":"Cohort 1 Mothers: Dapivirine (DPV) Vaginal Ring (VR)","type":"EXPERIMENTAL"},{"label":"Cohort 1 Mothers: Truvada Tablet","type":"EXPERIMENTAL"},{"label":"Cohort 2 Mothers: Dapivirine (DPV) Vaginal Ring (VR)","type":"EXPERIMENTAL"},{"label":"Cohort 2 Mothers: Truvada Tablet","type":"EXPERIMENTAL"},{"label":"Cohort 3 Mothers: Dapivirine (DPV) Vaginal Ring (VR)","type":"EXPERIMENTAL"},{"label":"Cohort 3 Mothers: Truvada Tablet","type":"EXPERIMENTAL"},{"label":"Cohort 1 Infants: Dapivirine (DPV) Vaginal Ring (VR)","type":"EXPERIMENTAL"},{"label":"Cohort 1 Infants: Truvada Tablet","type":"EXPERIMENTAL"},{"label":"Cohort 2 Infants: Dapivirine (DPV) Vaginal Ring (VR)","type":"EXPERIMENTAL"},{"label":"Cohort 2 Infants: Truvada Tablet","type":"EXPERIMENTAL"},{"label":"Cohort 3 Infants: Dapivirine (DPV) Vaginal Ring (VR)","type":"EXPERIMENTAL"},{"label":"Cohort 3 Infants: Truvada Tablet","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the maternal and infant safety of the dapivirine (DPV) vaginal ring (VR) and daily oral Truvada in HIV-uninfected pregnant women and their infants.","primaryOutcome":{"measure":"Number of Participants With a Composite Safety Endpoint Adverse Event (AE)","timeFrame":"Measured through participant's last study visit. For mothers, this occurred at approximately Week 12 to 36, depending on participant's cohort, and for infants at approximately Week 52.","effectByArm":[{"arm":"Cohort 1 Mothers: Dapivirine (DPV) Vaginal Ring (VR)","deltaMin":2,"sd":null},{"arm":"Cohort 1 Mothers: Truvada Tablet","deltaMin":6,"sd":null},{"arm":"Cohort 2 Mothers: Dapivirine (DPV) Vaginal Ring (VR)","deltaMin":16,"sd":null},{"arm":"Cohort 2 Mothers: Truvada Tablet","deltaMin":5,"sd":null},{"arm":"Cohort 3 Mothers: Dapivirine (DPV) Vaginal Ring (VR)","deltaMin":24,"sd":null},{"arm":"Cohort 3 Mothers: Truvada Tablet","deltaMin":4,"sd":null},{"arm":"Cohort 1 Infants: Dapivirine (DPV) Vaginal Ring (VR)","deltaMin":23,"sd":null},{"arm":"Cohort 1 Infants: Truvada Tablet","deltaMin":15,"sd":null},{"arm":"Cohort 2 Infants: Dapivirine (DPV) Vaginal Ring (VR)","deltaMin":30,"sd":null},{"arm":"Cohort 2 Infants: Truvada Tablet","deltaMin":10,"sd":null},{"arm":"Cohort 3 Infants: Dapivirine (DPV) Vaginal Ring (VR)","deltaMin":48,"sd":null},{"arm":"Cohort 3 Infants: Truvada Tablet","deltaMin":6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":10,"exclusionCount":9},"locations":{"siteCount":4,"countries":["Malawi","South Africa","Uganda","Zimbabwe"]},"refs":{"pmids":["40292084"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":101},"commonTop":["Upper respiratory tract infection","Weight gain poor","Gastroenteritis","Small for dates baby","Diarrhoea"]}}